American Vanguard’sQQ4 2024 results reflect a challenging year heavily burdened by nonrecurring impairment and transformation charges that culminated in a negative quarterly EBITDA and a substantial net loss. The company reported Q4 2024 revenue of $165.6 million and an EBITDA line that was negative by approximately $66.8 million in the quarter, driven largely by $76.0 million of asset impairments in Q4 (including SIMPAS, goodwill, and obsolescence-related write-downs) as part of a broader $118 million of nonrecurring charges for the calendar year 2024. The reported full-year top line was approximately $550-563 million on an unaudited basis (adjusted revenue) with adjusted EBITDA of about $42 million, implying an adjusted EBITDA margin of roughly 7.5%. Management frames these charges as an essential repositioning step intended to unlock higher profitability and growth in the medium term, anchored by a comprehensive transformation program (simplify, prioritize, deliver), ERP implementation, and a restructured operating model. 2025 guidance signals a revenue target of $565-585 million and EBITDA of $45-52 million, with capital expenditure around $10 million and a focus on debt reduction via free cash flow. Management expects margin leverage to emerge primarily from ongoing cost cuts, gross-margin enhancement (driven in part by portfolio simplification and operating efficiency), and higher inventory turns toward 2x by year-end 2025. The tone of the call reflects measured optimism: while 2025 is expected to be a bridge year with near-term EBITDA in the mid-to-high single digits as the transformation progresses, the long-run plan targets double-digit EBITDA growth as the company rationalizes its product portfolio and strengthens the balance sheet. Investors should monitor execution of the ERP deployment, the pace of margin expansion in H2 2025, progress on inventory management, tariff dynamics, and the ability to meaningfully de-lever the balance sheet.